Retrophin (RTRX) PT Raised to $32 at Leerink Partners Following Clear Efficacy from Sparsentan
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwatz reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $32.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
